Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Transforming Growth Factor Beta 1/SMAD2 Signalling Axis Regulates Leukemia Stem Cell Marker CD123: Implications for Acute Myeloid Leukemia

Sepideh Azizi Taramsary, Joanna Woodcock, Denis Tvorogov, Angel F. Lopez, Daniel Thomas

Blood (2024) 144 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2024-204191

Published: 2024

Journal Articles

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

Hazem Aboaid, Kevin Nguyen, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 7866.

https://doi.org/10.1182/blood-2024-211236

Published: 2024

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

Journal Articles

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Hazem Aboaid, Ramaditya Srinivasmurthy, Daniel Thomas Jones, Kevin Nguyen, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 7036.

https://doi.org/10.1182/blood-2024-209018

Published: 2024

Journal Articles

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Maha M Kamel, Nirmal Robinson, Monika Kutyna, Kelly Lim, Chloe Thompson-Peach, Steven W Lane, David T Yeung, Agnes S. M. Yong, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2024-204177

Published: 2024

Journal Articles

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Kelly Lim, Monika Kutyna, Winnie Kan, Angel F. Lopez, Anna Brown, Agnes S. M. Yong, Steven W Lane, Chun Yew Fong, Timothy P Hughes, David T Yeung, David M Ross, Devendra Hiwase, Daniel Thomas

Blood (2024) 144 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2024-202682

Published: 2024

Journal Articles

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Ilaria Stefania Pagani, Vaidehi Krishnan, John Ouyang, Chung How Kok, BeiJun Chen, Elyse C Page, Phuong Dang, Verity A Saunders, Jane James, Kelly Lim, Naranie Shanmuganathan, Susan Branford, Charles Chuah, David T Yeung, Daniel Thomas, Timothy P Hughes, Sin Tiong Ong, David M Ross

Blood (2024) 144 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2024-206591

Published: 2024

Journal Articles

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Devendra Hiwase, David M Ross, David T Yeung, Agnes S. M. Yong, Steven W Lane, Anna Brown, Chun Yew Fong, Timothy P Hughes, John Reynolds, Daniel Thomas

Blood (2024) 144 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2024-202867

Published: 2024

Journal Articles

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 2390.

https://doi.org/10.1182/blood-2024-211295

Published: 2024

Journal Articles

High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Shreyas Khanna, Harini Haran, Thomas Wiseman, Kevin Hung, Aidan Sapio, Philip Selby, Michaela Spooner, David T Yeung, Daniel Thomas, Chung How Kok, Andrew H Wei, Chong Chyn Chua, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 4237.

https://doi.org/10.1182/blood-2024-209258

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

Journal Articles

Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David T Yeung, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 1267.

https://doi.org/10.1182/blood-2024-212120

Published: 2024

Journal Articles

Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms

Monika Kutyna, Daniel Thomas, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 1304.

https://doi.org/10.1182/blood-2024-212301

Published: 2024

Journal Articles

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David M Ross, David T Yeung, Anna Brown, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2024-209123

Published: 2024

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation

Yanjing Vera Liu, Jeremiah Suryatenggara, Hannan Wong, Jing Ping Tang, Hong Kee Tan, Junsu Kwon, Qiling Zhou, Simone Ummarino, Alexander Ebralidze, John G. Doench, Li Chai, Touati Benoukraf, Devendra Hiwase, Daniel Thomas, Annalisa Di Ruscio, Daniel G. Tenen, Mahmoud Adel Bassal

Blood (2023) 142 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2023-182715

Published: 2023

Journal Articles

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Monika Kutyna, Maha M Kamel, David M. Ross, Agnes S. M. Yong, Chun Yew Fong, Chloe Thompson-Peach, Steven W. Lane, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2023-179706

Published: 2023

Journal Articles

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Devendra Hiwase, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2023-179688

Published: 2023

Journal Articles

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Maha M Kamel, Monika Kutyna, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2023-188340

Published: 2023

NARROW

Transforming Growth Factor Beta 1/SMAD2 Signalling Axis Regulates Leukemia Stem Cell Marker CD123: Implications for Acute Myeloid Leukemia

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia

Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only